CVS Health (CVS) Investor Day 2016 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2016 summary
4 Nov, 20262016 performance
Adjusted EPS expected at $5.77-$5.83, up 11.75%-13%; net revenue growth expected at 16%-16.5%.
FY16 free cash flow expected at $6.8B-$7B, with $6.9B cited as an accomplishment.
Approximately $6B expected to be returned to shareholders through dividends and buybacks.
2017 PBM selling season generated $7.8B in gross new business, with ~97% client retention; commercial client drug trend was 3.3% through September, net of rebates.
Specialty dispensed revenue forecast to grow ~19% in 2016; enterprise script and claim growth was ~19%, including Omnicare and Target pharmacies.
2017 outlook
Net revenue growth guidance of 4%-5.75%; adjusted EPS of $5.77-$5.93, a YoY change of (0.5%)-2.5%; GAAP diluted EPS of $5.02-$5.18.
Free cash flow guidance of $6B-$6.4B, down 7%-13% YoY; cash from operations of $7.7B-$8.6B.
PBM revenue growth expected at 8.5%-10.5% and operating profit growth at 6.5%-9.5%; retail/LTC revenue flat to down 1.5%, comp scripts flat to up 1%, and operating profit down 7%-9.5%.
Guidance reflects >40M lost prescriptions, slower Omnicare and Target accretion, and ongoing margin pressure; acquisitions expected to add $0.17 to EPS, below the originally anticipated pace.
Earnings growth expected to be significantly back-half weighted, reflecting calendar timing, generic launches, Medicare Part D and the streamlining initiative.
Long-term targets and cost efficiency
Steady-state targets: ~5% net revenue growth, ~6% operating profit growth and ~10% adjusted EPS growth; annual free cash flow target of $7B-$8B.
Multi-year streamlining targets $700M-$750M in annual savings by 2021 and $3B cumulative savings over five years; savings expected to exceed costs beginning in 2018.
Plan includes closing ~70 stores, consolidating back-office shared services and redistributing prescription fulfillment work; closures carry a $265M estimated charge, largely in 2017.
Relocated shared-services activities achieved 15%-20% labor cost reductions; adjusted debt/EBITDA target remains ~2.7x, with debt reduction planned as maturities come due.
Latest events from CVS Health
- Separation aims to unlock standalone growth while preserving investment-grade balance sheets.CVS
8th Annual Wolfe Research Healthcare Conference - Care delivery expansion and post-deleveraging capital choices shape the forward strategy.CVS
30th Annual Credit Suisse Healthcare Conference - PBM cost controls, health plan growth and integrated care underpin the outlook.CVS
The 2016 Morgan Stanley Global Healthcare Conference - Integrated pharmacy scale supported growth and more than $5B in planned 2016 shareholder returns.CVS
The UBS 2016 Global Healthcare Conference - Integrated pharmacy and clinical programs aim to improve outcomes and reduce care costs.CVS
UBS Global Healthcare Conference 2017 - Signify bolsters in-home care and value-based strategy amid stable utilization.CVS
Morgan Stanley 20th Annual Global Healthcare Conference - Aetna integration targets >$750M in 2020 synergies and broader medical-cost savings.CVS
JP Morgan 37th Annual Healthcare conference - A $77B Aetna deal targets integrated care and $750M in year-two synergies.CVS
M&A announcement - FY18 operating profit growth guided to 1%–4%, tempered by PBM and deal-related headwinds.CVS
Guidance